KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Nektar Therapeutics (NKTR) Net Income towards Common Stockholders (2016 - 2025)

Historic Net Income towards Common Stockholders for Nektar Therapeutics (NKTR) over the last 16 years, with Q3 2025 value amounting to -$35.0 million.

  • Nektar Therapeutics' Net Income towards Common Stockholders rose 558.33% to -$35.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$113.4 million, marking a year-over-year increase of 3263.14%. This contributed to the annual value of -$119.0 million for FY2024, which is 5689.72% up from last year.
  • According to the latest figures from Q3 2025, Nektar Therapeutics' Net Income towards Common Stockholders is -$35.0 million, which was up 558.33% from -$39.2 million recorded in Q2 2025.
  • In the past 5 years, Nektar Therapeutics' Net Income towards Common Stockholders ranged from a high of $7.2 million in Q4 2024 and a low of -$159.1 million during Q2 2022
  • For the 5-year period, Nektar Therapeutics' Net Income towards Common Stockholders averaged around -$74.5 million, with its median value being -$52.4 million (2024).
  • In the last 5 years, Nektar Therapeutics' Net Income towards Common Stockholders tumbled by 5689.88% in 2021 and then surged by 11719.15% in 2024.
  • Nektar Therapeutics' Net Income towards Common Stockholders (Quarter) stood at -$146.9 million in 2021, then soared by 54.66% to -$66.6 million in 2022, then skyrocketed by 36.82% to -$42.1 million in 2023, then soared by 117.19% to $7.2 million in 2024, then plummeted by 583.66% to -$35.0 million in 2025.
  • Its Net Income towards Common Stockholders stands at -$35.0 million for Q3 2025, versus -$39.2 million for Q2 2025 and -$46.4 million for Q1 2025.